Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Shares Issued (2016 - 2025)

Historic Shares Issued for Avalo Therapeutics (AVTX) over the last 10 years, with Q2 2025 value amounting to $40000.0.

  • Avalo Therapeutics' Shares Issued changed N/A to $40000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $67.6 million, marking a year-over-year decrease of 3742.83%. This contributed to the annual value of $115.6 million for FY2024, which is 25609.79% up from last year.
  • Latest data reveals that Avalo Therapeutics reported Shares Issued of $40000.0 as of Q2 2025.
  • In the past 5 years, Avalo Therapeutics' Shares Issued ranged from a high of $108.1 million in Q1 2024 and a low of -$14.8 million during Q4 2022
  • In the last 5 years, Avalo Therapeutics' Shares Issued had a median value of $16.2 million in 2023 and averaged $28.9 million.
  • Per our database at Business Quant, Avalo Therapeutics' Shares Issued skyrocketed by 86844.14% in 2021 and then soared by 68629.62% in 2024.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Shares Issued stood at $37.7 million in 2021, then tumbled by 139.39% to -$14.8 million in 2022, then skyrocketed by 226.24% to $18.7 million in 2023, then soared by 261.07% to $67.6 million in 2024, then crashed by 99.94% to $40000.0 in 2025.
  • Its Shares Issued was $40000.0 in Q2 2025, compared to $67.6 million in Q4 2024 and $108.1 million in Q1 2024.